Richard Gaynor, M.D.
Richard Gaynor joined Neon Therapeutics in 2016. Previously, from 2013 until his departure in 2016, he held the position of senior vice president of global product development and medical affairs at Lilly Oncology.
Richard began his career in academia, spending nine years on the faculty at UCLA School of Medicine, followed by 11 years on the faculty at the University of Texas Southwestern Medical School, including time serving as the chief of hematology-oncology and director of the Simmons Cancer Center. In 2002, he moved to Eli Lilly, where he began his industry career overseeing both oncology drug discovery and early clinical development. Richard chaired the Lilly Oncology Research and Development Committee and helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck, AstraZeneca and GE. In total, Richard spent 15 years in a series of senior roles at Lilly Oncology where he led preclinical and early clinical research , directed the biomarker and research group and served on key company portfolio review committees. He is the author of nearly 150 publications and participates on numerous advisory boards and committees, including several with the AACR, the Stand Up To Cancer scientific advisory committee, the MD Anderson Moon Shots advisory board, the Damon Runyon Cancer Research Foundation and Accelerating Cancer Cures.
Richard holds an M.D. from the University of Texas Southwestern Medical School and, following his residency in internal medicine there, he completed fellowship training in hematology-oncology at the UCLA School of Medicine.